You are here

  • Home
  • Archive
  • Volume 2, Issue 1
  • The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma

Article info

Article menu

Download PDFPDF

Research Article
The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma
Free

Authors

  • Minghui Li GRU Cancer CenterGeorgia Regents University 30912 Augusta, Georgia USA Program in Cancer immunology, Inflammation and Tolerance (CIT)Georgia Regents University Augusta GA USA Medical College of Georgia Department of PediatricsGeorgia Regents University 1120 Fifteenth Street CN-4141A Augusta GA USA PubMed articlesGoogle scholar articles
  • Aaron R Bolduc GRU Cancer CenterGeorgia Regents University 30912 Augusta, Georgia USA Program in Cancer immunology, Inflammation and Tolerance (CIT)Georgia Regents University Augusta GA USA Department of SurgeryGeorgia Regents University Augusta GA USA PubMed articlesGoogle scholar articles
  • Md Nasrul Hoda Department of NeurologyGeorgia Regents University Augusta GA USA College of Allied Health Sciences Department of Medical Laboratory, Imaging & Radiologic SciencesGeorgia Regents University 30912 Augusta GA USA PubMed articlesGoogle scholar articles
  • Denise N Gamble GRU Cancer CenterGeorgia Regents University 30912 Augusta, Georgia USA Program in Cancer immunology, Inflammation and Tolerance (CIT)Georgia Regents University Augusta GA USA PubMed articlesGoogle scholar articles
  • Sarah-Bianca Dolisca Medical College of Georgia Department of PediatricsGeorgia Regents University 1120 Fifteenth Street CN-4141A Augusta GA USA PubMed articlesGoogle scholar articles
  • Anna K Bolduc GRU Cancer CenterGeorgia Regents University 30912 Augusta, Georgia USA Program in Cancer immunology, Inflammation and Tolerance (CIT)Georgia Regents University Augusta GA USA PubMed articlesGoogle scholar articles
  • Kelly Hoang Medical College of Georgia Department of PediatricsGeorgia Regents University 1120 Fifteenth Street CN-4141A Augusta GA USA PubMed articlesGoogle scholar articles
  • Claire Ashley Medical College of Georgia Department of PediatricsGeorgia Regents University 1120 Fifteenth Street CN-4141A Augusta GA USA PubMed articlesGoogle scholar articles
  • David McCall GRU Cancer CenterGeorgia Regents University 30912 Augusta, Georgia USA Program in Cancer immunology, Inflammation and Tolerance (CIT)Georgia Regents University Augusta GA USA PubMed articlesGoogle scholar articles
  • Amyn M Rojiani GRU Cancer CenterGeorgia Regents University 30912 Augusta, Georgia USA Department of PathologyGeorgia Regents University Augusta GA USA PubMed articlesGoogle scholar articles
  • Bernard L Maria GRU Cancer CenterGeorgia Regents University 30912 Augusta, Georgia USA Medical College of Georgia Department of PediatricsGeorgia Regents University 1120 Fifteenth Street CN-4141A Augusta GA USA Department of NeurologyGeorgia Regents University Augusta GA USA Department of NeurosurgeryGeorgia Regents University Augusta GA USA PubMed articlesGoogle scholar articles
  • Olivier Rixe GRU Cancer CenterGeorgia Regents University 30912 Augusta, Georgia USA Department of MedicineGeorgia Regents University Augusta GA USA PubMed articlesGoogle scholar articles
  • Tobey J MacDonald Aflac Cancer & Blood Disorders Center, Children’s Healthcare of AtlantaEmory University School of Medicine 30322 Atlanta GA USA PubMed articlesGoogle scholar articles
  • Peter S Heeger Department of Medicine, Division of NephrologyThe Immunology Institute 10025 New York NY USA Recanati-Miller Transplant InstituteIcahn School of Medicine at Mount Sinai 10025 New York NY USA PubMed articlesGoogle scholar articles
  • Andrew L Mellor GRU Cancer CenterGeorgia Regents University 30912 Augusta, Georgia USA Program in Cancer immunology, Inflammation and Tolerance (CIT)Georgia Regents University Augusta GA USA Department of MedicineGeorgia Regents University Augusta GA USA PubMed articlesGoogle scholar articles
  • David H Munn GRU Cancer CenterGeorgia Regents University 30912 Augusta, Georgia USA Program in Cancer immunology, Inflammation and Tolerance (CIT)Georgia Regents University Augusta GA USA Medical College of Georgia Department of PediatricsGeorgia Regents University 1120 Fifteenth Street CN-4141A Augusta GA USA PubMed articlesGoogle scholar articles
  • Theodore S Johnson GRU Cancer CenterGeorgia Regents University 30912 Augusta, Georgia USA Program in Cancer immunology, Inflammation and Tolerance (CIT)Georgia Regents University Augusta GA USA Medical College of Georgia Department of PediatricsGeorgia Regents University 1120 Fifteenth Street CN-4141A Augusta GA USA PubMed articlesGoogle scholar articles

Citation

Li M, Bolduc AR, Hoda MN, et al
The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma
Journal for ImmunoTherapy of Cancer 2014;2:21. doi: 10.1186/2051-1426-2-21
Online issue publication 
February 09, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). 2014